Arcutis submits roflumilast cream for treating plaque psoriasis in patients aged 2 to 11 years
December 19th 2022Arcutis Biotherapeutics, Inc has submitted a supplemental New Drug Application for roflumilast cream (ZORYVE) to the US Food and Drug Administration for treatment of plaque psoriasis in children aged 2 to 11 years.